AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Transfusion-related acute lung injury (TRALI) Screening

Technology Benefits

Prevention of death related to TRALI.

Technology Application

Screening of donors for TRALI antibodies.

Detailed Technology Description

For decades, human neutrophil antigen (HNA) HNA-3a was thought to be involved in the condition known as Transfusion-related acute lung injury (TRALI); currently the leading cause of transfusion-related mortality reported to the FDA. However, until recently, little was known about the specific properties of HNA-3a. BloodCenter inventors, Brian Curtis and Dick Aster, have been working to identify the molecular properties of the HNA-3a or ΓÇ£5bΓÇØ antigen and its role in fatal TRALI. They identified the carrier protein for HNA-3a and determined the molecular basis of the HNA-3a/b polymorphism.Work in progress will facilitate low cost, large scale typing of donor populations to identify persons who are HNA-3a negative (5% of the general population). Blood donor typing will identify those who are at risk to have HNA-3a-specific antibodies. Methods should enable detection of antibodies specific for HNA-3b, the incidence and significance of which is not yet known.Patent pending

Country/Region

USA

For more information, please click Here